KLK3 and prostate cancer: There is also the possibility to combine ct-DNA with circulating proteins (prostate-specific antigen in prostate cancer) or with imaging (combination of ct-DNA and MRI imaging) [25,26,27] to improve the informative data setting linked to molecular biomarkers in MRD monitoring.